We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Adding TransDigm to Your Portfolio Makes Sense
Read MoreHide Full Article
TransDigm Group Incorporated (TDG - Free Report) managed to impress investors with its recent earnings streak as the company’s bottom line trumped estimates thrice in the trailing four quarters. We believe that the company’s strong operational efficiency, its solid portfolio of products as well as complementary acquisitions will continue to be key growth drivers, going forward.
The company’s stock has had an impressive run on the bourse in the past three months, driven by some impressive growth boosters. The stock has rallied 17.4%, ahead of the industry’s growth of 2.5%. We believe that the company’s encouraging traction across markets and a robust product portfolio will propel growth.
Read on to find out the key catalysts for the company right now.
Factors at Play
TransDigm’s excellent business operation model, which implements value-based operating strategies guided by three value driver concepts, has helped the company generate sufficient organic and inorganic growth, expanding the operating margin over the past few quarters.
Moreover, through its well-diversified business, the company offers a broad range of products to its customers. Notably, it designs, produces and supplies highly engineered proprietary aerospace components and certain systems, commanding a significant aftermarket presence. For instance, 90% of TransDigm’s net sales is generated from the proprietary engineered products the intellectual property right of which, the company owns and enjoys to enhance its competitive edge. Also, the company is the sole supplier of more than three-fourth of products that it sells. This in turn, cements its assertive foothold in the market quite meaningfully.
Further, we believe that stable aftermarkets, which have historically produced higher gross margins, will continue to leverage the company’s financial performance in the upcoming quarters. Of late, this Zacks Rank #2 (Buy) player’s defense business has also been steady enough to consistently add to its strength.
This apart, the company’s acquisition strategies are directed toward buying proprietary aerospace businesses with substantial aftermarket content. This tactical move has in fact, already helped TransDigm strengthen its footprint in the core markets and grab a higher market share. In this regard, the company during fiscal 2017, had announced the buyout of three add-on aerospace product lines for a total consideration of roughly $100 million.
We are also highly optimistic about TransDigm’s consolidations of Kirkhill and Extant in March 2018. Both companies are primarily proprietary sole source aerospace businesses with sizeable aftermarket content. Such strategic transactions are expected to be accretive to the acquirer’s product portfolio and contribute to its long-term growth.
AeroVironment surpassed estimates in three of the trailing four quarters with an average positive earnings surprise of 147.4%.
CPI Aerostructures exceeded estimates thrice in the last four quarters with an average beat of 20.1%.
KLX outpaced estimates thrice in the preceding four quarters with an average earnings surprise of 10.6%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Here's Why Adding TransDigm to Your Portfolio Makes Sense
TransDigm Group Incorporated (TDG - Free Report) managed to impress investors with its recent earnings streak as the company’s bottom line trumped estimates thrice in the trailing four quarters. We believe that the company’s strong operational efficiency, its solid portfolio of products as well as complementary acquisitions will continue to be key growth drivers, going forward.
The company’s stock has had an impressive run on the bourse in the past three months, driven by some impressive growth boosters. The stock has rallied 17.4%, ahead of the industry’s growth of 2.5%. We believe that the company’s encouraging traction across markets and a robust product portfolio will propel growth.
Read on to find out the key catalysts for the company right now.
Factors at Play
TransDigm’s excellent business operation model, which implements value-based operating strategies guided by three value driver concepts, has helped the company generate sufficient organic and inorganic growth, expanding the operating margin over the past few quarters.
Moreover, through its well-diversified business, the company offers a broad range of products to its customers. Notably, it designs, produces and supplies highly engineered proprietary aerospace components and certain systems, commanding a significant aftermarket presence. For instance, 90% of TransDigm’s net sales is generated from the proprietary engineered products the intellectual property right of which, the company owns and enjoys to enhance its competitive edge. Also, the company is the sole supplier of more than three-fourth of products that it sells. This in turn, cements its assertive foothold in the market quite meaningfully.
Further, we believe that stable aftermarkets, which have historically produced higher gross margins, will continue to leverage the company’s financial performance in the upcoming quarters. Of late, this Zacks Rank #2 (Buy) player’s defense business has also been steady enough to consistently add to its strength.
This apart, the company’s acquisition strategies are directed toward buying proprietary aerospace businesses with substantial aftermarket content. This tactical move has in fact, already helped TransDigm strengthen its footprint in the core markets and grab a higher market share. In this regard, the company during fiscal 2017, had announced the buyout of three add-on aerospace product lines for a total consideration of roughly $100 million.
We are also highly optimistic about TransDigm’s consolidations of Kirkhill and Extant in March 2018. Both companies are primarily proprietary sole source aerospace businesses with sizeable aftermarket content. Such strategic transactions are expected to be accretive to the acquirer’s product portfolio and contribute to its long-term growth.
Other Stocks to Consider
Other top-ranked stocks in the same space include AeroVironment, Inc. (AVAV - Free Report) , CPI Aerostructures, Inc. (CVU - Free Report) and KLX Inc. . While AeroVironment sports a Zacks Rank #1 (Strong Buy), CPI Aerostructures and KLX carry a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
AeroVironment surpassed estimates in three of the trailing four quarters with an average positive earnings surprise of 147.4%.
CPI Aerostructures exceeded estimates thrice in the last four quarters with an average beat of 20.1%.
KLX outpaced estimates thrice in the preceding four quarters with an average earnings surprise of 10.6%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>